A phase 1b clinical trial showed that following administration of PF-4136309 in patients with pancreatic ductal adenocarcinoma (PDAC), levels of CD14 + CCR2+ inflammatory monocytes reduced in the peripheral blood (157). Here, CD14 is linked to pancreatic ductal adenocarcinoma.